Memantine Zentiva (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA receptor, blocking excessive calcium entry caused by over‑activation of glutamate pathways. This reduces excitotoxic neuronal damage, which is thought to contribute to the cognitive decline seen in Alzheimer’s disease.

The specific dose and titration schedule for Memantine Zentiva are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (e.g., donepezil) target acetylcholine metabolism. Memantine is typically used in moderate to severe stages, often in combination with a cholinesterase inhibitor for additive benefit.

Memantine Zentiva should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Memantine Zentiva is taken orally, usually as a tablet, with or without food. The exact administration schedule—once daily or divided doses—depends on the prescriber’s dosing plan and the patient’s tolerance.

Serious adverse events, although rare, can include seizures, severe psychiatric reactions such as hallucinations or psychosis, cardiac arrhythmias, and significant liver enzyme elevations. Patients should be monitored for these symptoms and seek immediate medical attention if they occur.

Memantine is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists.